Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3)

The summary for the Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3): The National Institute on Drug Abuse (NIDA) invites cooperative agreement applications from qualified non-profit, private and academic researchers/organizations to participate in the planning and execution of a new public-private partnership (PPP). The purpose of a one-year planning phase (UH2) is to provide support for the systematic study directed toward fuller scientific understanding of the opportunities in the area of drug discovery and development for tobacco dependence, with the ultimate goal of establishing a PPP, specifically, a Product Development Partnership (PDP). The mission of the PDP is to develop safe and effective medications for the treatment of tobacco dependence, including aids for smoking cessation. Phase two (UH3) funding will be utilized to support the implementation and execution phase of the PDP, with one selected cooperative agreement recipient assuming the role of the PDPs Managing Partner. In this subsequent phase, the PDP will conduct a wide array of research and development (R&D) projects aimed at the fulfillment of regulatory requirements for approval for marketing in the US.
Federal Grant Title: Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-11-015
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: Apr 26, 2011
Original Application Deadline: Apr 26, 2011
Posted Date: February 22nd, 2011
Creation Date: Feb 22, 2011
Archive Date: May 27, 2011
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are allowed
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
Clinical Sites for the ECHO IDeA States Pediatric Clinical Trials Network - 2 (UG1 Clinica...
Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials...
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Tri...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Al...
Resource-Related Research Projects for Development of Animal Models and Related Materials ...
Tailoring Interventions to Improve Preventive Health Service Use (R61/R33 Clinical Trial R...
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinica...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com